Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APVONASDAQ:CDTNASDAQ:CFRXNASDAQ:PTIX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$4.39-8.2%$10.13$4.30▼$606.35$1.78M5.7576,447 shs53,332 shsCDTConduit Pharmaceuticals$2.33-5.7%$6.72$2.31▼$4,680.00$1.86M2.02150,453 shs201,049 shsCFRXContraFect$0.05$0.05$0.04▼$13.02$535K0.291.39 million shs910,216 shsPTIXProtagenic Therapeutics$3.32-5.7%$3.84$2.35▼$15.82$1.96M0.36559,982 shs61,566 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics+2.80%0.00%-29.71%-90.08%-99.98%CDTConduit Pharmaceuticals-2.37%-8.52%-58.48%-84.89%-99.92%CFRXContraFect0.00%0.00%0.00%0.00%0.00%PTIXProtagenic Therapeutics-0.28%+1.15%+0.28%-4.73%-72.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPVOAptevo Therapeutics3.2243 of 5 stars3.55.00.00.04.10.00.6CDTConduit Pharmaceuticals0.1933 of 5 stars0.02.00.00.02.70.00.0CFRXContraFectN/AN/AN/AN/AN/AN/AN/AN/APTIXProtagenic Therapeutics1.3554 of 5 stars0.04.00.00.04.11.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics 3.00Buy$219,040.004,989,421.64% UpsideCDTConduit Pharmaceuticals 4.00Strong BuyN/AN/ACFRXContraFect 0.00N/AN/AN/APTIXProtagenic Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo Therapeutics$3.11M0.57N/AN/A$3.26 per share1.35CDTConduit PharmaceuticalsN/AN/AN/AN/A($0.62) per shareN/ACFRXContraFectN/AN/AN/AN/A($19.92) per shareN/APTIXProtagenic TherapeuticsN/AN/AN/AN/A$0.83 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-488.93%-152.51%8/6/2025 (Estimated)CDTConduit Pharmaceuticals-$540K-$534.48N/A∞N/AN/AN/A-328.67%N/ACFRXContraFect-$65.15M-$19.27N/AN/AN/AN/AN/A-138.70%N/APTIXProtagenic Therapeutics-$5M-$13.11N/A∞N/AN/A-308.97%-228.73%8/12/2025 (Estimated)Latest CFRX, PTIX, CDT, and APVO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025APVOAptevo Therapeutics-$84.20-$87.80-$3.60-$4.39N/AN/A5/15/2025Q1 2025CDTConduit PharmaceuticalsN/A-$19.80N/A-$1.32N/AN/A5/13/2025Q1 2025PTIXProtagenic TherapeuticsN/A-$2.75N/A-$2.75N/AN/A3/31/2025Q4 2024PTIXProtagenic TherapeuticsN/A-$3.36N/A-$0.24N/AN/A3/28/2025Q4 2024CDTConduit PharmaceuticalsN/A-$304.95N/A-$20.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/ACDTConduit PharmaceuticalsN/AN/AN/AN/AN/ACFRXContraFectN/AN/AN/AN/AN/APTIXProtagenic TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A1.721.72CDTConduit PharmaceuticalsN/A0.120.12CFRXContraFectN/A0.530.53PTIXProtagenic TherapeuticsN/A1.801.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%CDTConduit Pharmaceuticals3.29%CFRXContraFect7.85%PTIXProtagenic Therapeutics7.97%Insider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics0.01%CDTConduit Pharmaceuticals4.05%CFRXContraFect0.62%PTIXProtagenic Therapeutics35.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics50405,0001.46 millionNot OptionableCDTConduit Pharmaceuticals3798,000710,000Not OptionableCFRXContraFect2310.70 million10.64 millionNot OptionablePTIXProtagenic Therapeutics2589,0004.71 millionNot OptionableCFRX, PTIX, CDT, and APVO HeadlinesRecent News About These CompaniesProtagenic & Phytanix Merge in All-Stock Move, Sparking Retail FrenzyMay 29, 2025 | msn.comProtagenic Therapeutics swaps warrants for sharesMay 21, 2025 | uk.investing.comProtagenic Therapeutics and Phytanix merge in all stock dealMay 21, 2025 | thepharmaletter.comProtagenic Therapeutics Receives $3.1 Million from Recent Warrant ActivityMay 21, 2025 | accessnewswire.comProtagenic Therapeutics Shares Double After Buyout Offer From Phytanix BioMay 20, 2025 | marketwatch.comProtagenic Therapeutics stock soars on merger to create Neuroactive Biopharmaceutical companyMay 20, 2025 | in.investing.comProtagenic Therapeutics Merges With Phytanix Bio In All-Stock Deal: Retail Turns Extremely BullishMay 20, 2025 | msn.comProtagenic Therapeutics Soars 190% on Merger to Launch Neuroactive Biopharma FirmMay 20, 2025 | msn.comPTIX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Protagenic Therapeutics, Inc. Is Fair to ShareholdersMay 19, 2025 | businesswire.comProtagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic DisordersMay 19, 2025 | accessnewswire.comProtagenic Therapeutics Inc.May 9, 2025 | barrons.comProtagenic Therapeutics, Inc.: Protagenic Therapeutics to Effect 1-for-14 Reverse Stock SplitApril 29, 2025 | finanznachrichten.deProtagenic Therapeutics to Effect 1-for-14 Reverse Stock SplitApril 29, 2025 | accessnewswire.comProtagenic Therapeutics adjusts stock option pricesFebruary 26, 2025 | uk.investing.comPTIX stock touches 52-week low at $0.25 amid sharp annual declineFebruary 11, 2025 | msn.comAvalon Holdings (AMEX:AWX) Stock Quotes, Forecast and News SummaryJanuary 31, 2025 | benzinga.comPerformance Tech stock hits 52-week low at $0.4January 30, 2025 | msn.comProtagenic Therapeutics Inc (PTIX) Stock Settles at $0.53: What’s Contributing to This Price Point?December 24, 2024 | bovnews.comProtagenic Therapeutics faces Nasdaq delisting over equity deficitDecember 5, 2024 | investing.comProtagenic Therapeutics Inc (PTIX) Stock Sees Market Value Hit $3.57 million: What Are the Implications?November 13, 2024 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCFRX, PTIX, CDT, and APVO Company DescriptionsAptevo Therapeutics NASDAQ:APVO$4.39 -0.39 (-8.16%) Closing price 04:00 PM EasternExtended Trading$4.80 +0.41 (+9.23%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Conduit Pharmaceuticals NASDAQ:CDT$2.33 -0.14 (-5.67%) Closing price 04:00 PM EasternExtended Trading$2.33 0.00 (-0.21%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.ContraFect NASDAQ:CFRXContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.Protagenic Therapeutics NASDAQ:PTIX$3.32 -0.20 (-5.68%) Closing price 04:00 PM EasternExtended Trading$3.33 +0.01 (+0.30%) As of 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
